Mani Mohindru, PhD

Dr. Mohindru is an experienced biotech executive with several years of biopharmaceutical industry leadership as well as Wall Street experience. In addition to Roshon, she also serves as a member of the board of directors of CytomX Therapeutics (Nasdaq: CTMX) and Cardiff Oncology (Nasdaq: CTMX). Previously, she was the CEO and Board Director of Novasenta, as well as CereXis, two private biotechnology companies. She has also held senior leadership positions in public biotech companies, having served as Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc., and Chief Strategy Officer of Curis, Inc.

Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. 

Currently, she also serves on the Executive Advisory Board of the CLP Institute of Northwestern University and the Scientific Investment Advisory Committee of the Gates Institute at University of Colorado.

​Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and completed B.S. in Human Biology and Masters in Biotechnology from the All India Institute of Medical Sciences, New Delhi, India.